Author: Sam Hope, CEO, Beyond Blue
We just published a new whitepaper on AI in market research, specifically where it actually belongs in the insight ecosystem, and its impact on decision-making, and one part of it tends to surprise people: in our own framework, AI ranks lowest.
Data is abundant. Judgment is scarce.
Pharmaceutical market research teams have more data available today than at any point before. Between primary research, social listening, and AI-generated synthesis, most teams now have far more inputs than they can realistically process manually. The instinct, understandably, is to let AI make sense of it all because it’s fast, it can work through a mountain of research in minutes, and it hands back something that looks like clarity.
That’s exactly the moment to slow down. AI outputs can look convincing before the underlying evidence is strong enough to actually support them. Any input, AI included, earns trust the same way: through evidence, over time, at the right stage.
AI-enhanced, not AI-led
This is where our new framework comes in. We mapped out how much weight AI should carry at each stage of an asset’s lifecycle, treating that weight as something that grows deliberately rather than something fixed on day one.
What this means for insight teams: AI’s authority scales with the evidence behind it, on a timeline the team stays in the curator’s seat to set.
The risks of moving too fast
Two patterns show up again and again in early-stage work: pressure to prove AI’s value quickly, and sheer data volume, multiple stakeholder groups, a wide range of indications, and dozens of possible inputs all competing for attention at once. Together, they create a specific kind of hesitancy. Greenbook’s 2026 GRIT Insights Practice Report backs this up directly, showing that confidence in AI risk management correlates with exceeding business goals. The whitepaper walks through exactly how each risk shows up, and the sequencing that keeps them from compounding.
How AI’s role evolves across the asset lifecycle
In our framework, AI’s weight shifts across four distinct stages as an asset matures, starting well behind desk research and primary market research, and finishing as the lead voice by launch. Each promotion is earned against specific evidence thresholds, grounded in what the evidence actually shows, and our whitepaper lays out those thresholds stage by stage.
Read the full insight ecosystem framework
The whitepaper walks through all four lifecycle stages, both risks in full, and the four steps we take early on to set AI up for greater utility later.
It’s based on our talk “Take yourself from more data to better decisions by knowing when not to lead with AI in the insight ecosystem era”, presented by Phil Barnes at this year’s EPHMRA conference. The whitepaper is the deeper, written version, covering everything at your own pace.
If you’d like to talk through how this framework could apply to your own pharmaceutical market research pipeline, get in touch today.
Frequently asked questions
Why not let AI lead market research and have a person review the output at the end?
Because review happens too late to catch the real risk. AI often produces persuasive content prematurely, before the supporting evidence is robust enough to validate it. Our whitepaper breaks down the three guardrails that catch this earlier in the process.
What actually determines when AI is ready for a bigger role in pharmaceutical market research?
It comes down to a small set of specific conditions tied purely to evidence strength, the discipline behind responsible AI in practice. We spell out exactly what those conditions are, and how to apply them at each lifecycle stage, in the full framework.
What does curating the ecosystem actually look like day to day?
It’s a short, practical list of habits, and most teams are already doing some version of the first two without realizing it. The whitepaper lays out all four, along with what changes when you do them deliberately instead of by accident.